淋巴瘤免疫化疗后急性肝炎再活动挽救性抗病毒治疗的临床观察  

Efficacy of rescue antiviral therapy in lymphoma patients with acute exacerbations of hepatitis B after chemotherapy in combination with rituximab

作　　者：董敏[1] 魏丽[1] 林曲[1] 李星[1] 温景芸[1] 马小琨[1] 陈展洪[1] 吴祥元[1] 

机构地区：[1]中山大学附属第三医院肿瘤内科,广东广州510630

出　　处：《中华肿瘤防治杂志》2011年第21期1717-1719,共3页Chinese Journal of Cancer Prevention and Treatment

基　　金：广东省医学科学基金(A2010179)

摘　　要：目的:初步分析挽救性抗病毒治疗对于淋巴瘤免疫化疗后急性肝炎再活动的价值。方法:回顾性分析19例经免疫化疗后出现急性肝炎再活动的淋巴瘤患者的临床特征、挽救性抗病毒治疗方案及治疗效果,使用受试者工作特征(ROC)及Kap-lan-Meier曲线分析病毒应答时间及不同抗病毒策略的价值。结果:在19例患者中,10例肝炎活动治愈,13例达到病毒应答,病毒应答时间≤7周,联合抗病毒治疗策略组患者总生存较病毒应答时间>7周,单药抗病毒治疗组患者可能提高,但是差异无统计学意义。结论:病毒应答时间较短的挽救性抗病毒治疗对于经免疫化疗后急性肝炎再活动的淋巴瘤患者可能具有一定治疗价值。OBJECTIVE： To evaluate the role of rescue antivi- ral therapy in the treatment of acute exacerbations of hepatitis B af- ter chemotherapy in combination with rituximab. METHODS： A ret rospeetive study was conducted on the records of a total of 19 Chinese lymphoma patients who suffered this complication in order to characterize the rescue antiviral therapy. Receiver operating characteristic （ROC） a- nalysis and Kaplan-Meier survival analysis were utilized to determine the potential superior antiviral strategy. RESULTS： Ten of the 19 patients survived of the hepatitis flare and 13 of them reached virological response with median time of 7 weeks. The overall survival of the patients with virus response time ≤ 7 weeks or received combination antiviral therapy seemed to be longer than the patients with virus response time 〉 7 weeks or received single agent antiviral therapy. CONCLUSION： Rescue antiviral therapy for acute exacerbations of hepatitis B, which provides a shortened viral response time, may be of potential survival benefit and remain to be further characterized.

关 键 词：肝炎 乙型 淋巴瘤 拉米夫定 药物疗法 

分 类 号：R512.62[医药卫生—内科学] R733.1[医药卫生—临床医学]